BioCentury
ARTICLE | Distillery Therapeutics

Therapeutics: MAP kinase kinase kinase kinase 3 (MAP4K3; GLK); kruppel-like factor 2 (KLF2); kruppel-like factor 4 (KLF4; EZF)

April 7, 2016 7:00 AM UTC

Patient sample and mouse studies suggest inhibiting the MAP4K3-KLF2/KLF4 pathway could help treat cerebral cavernous malformations (CCMs), which involve the formation of highly dilated blood vessels a...